Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ODC1 | P11926 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | BLM | P54132 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10924419 | 0.84 | ODC1 (0.45) | SMN1; SMN2HIF1AODC1LMNABLM | |
| SCHEMBL8991294 | 0.82 | SMN1; SMN2 (0.32) | SMN1; SMN2HIF1ABLMKMT2APMP22 | |
| SCHEMBL349825 | 0.80 | GLRA1 (0.38) | SMN1; SMN2HIF1AODC1KDM4EARG1 | |
| SCHEMBL825611 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1AODC1LMNABLM | |
| SCHEMBL4278877 | 0.79 | ODC1 (0.46) | SMN1; SMN2HIF1AODC1LMNABLM | |
| SCHEMBL5960916 | 0.77 | FAAH (0.48) | KMT2ACYP1A2TSHRHDAC11MEN1 | |
| SCHEMBL8601948 | 0.76 | SMN1; SMN2 (0.34) | SMN1; SMN2HIF1AODC1LMNABLM | |
| SCHEMBL619053 | 0.76 | TSHR (0.35) | SMN1; SMN2HIF1ATSHRARG1ARG2 | |
| SCHEMBL19066818 | 0.76 | FAAH (0.50) | KMT2ACYP1A2TSHRHDAC11MEN1 | |
| SCHEMBL17701346 | 0.76 | FAAH (0.50) | KMT2ACYP1A2TSHRHDAC11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7601753-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7354923-B2 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7189755-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1425029-A4 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005079574-A1 | BICYCLIC MELANOCORIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1425029-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | Palatin Technologies, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003013571-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | SMN1; SMN2 2699/4885HIF1A 4449/4885ODC1 1362/4885 |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | SMN1; SMN2 3054/4885HIF1A 3914/4885ODC1 2434/4885 |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | MC3R, MC1R, MC5R | SMN1; SMN2 2920/4885HIF1A 4405/4885ODC1 1083/4885 |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | SMN1; SMN2 2772/4885HIF1A 4393/4885ODC1 1426/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | SMN1; SMN2 2738/4885HIF1A 2810/4885ODC1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.